Display options
Cite
Gild ML, Naik N, Hoang J, et al. Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clin Endocrinol (Oxf). 2018;89(2):139-147doi: 10.1111/cen.13737.
Gild, M. L., Naik, N., Hoang, J., Hsiao, E., McGrath, R. T., Sywak, M., Sidhu, S., Delbridge, L. W., Robinson, B. G., Schembri, G., & Clifton-Bligh, R. J. (2018). Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clinical endocrinology, 89(2), 139-147. https://doi.org/10.1111/cen.13737
Gild, Matti L, et al. "Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas." Clinical endocrinology vol. 89,2 (2018): 139-147. doi: https://doi.org/10.1111/cen.13737
Gild ML, Naik N, Hoang J, Hsiao E, McGrath RT, Sywak M, Sidhu S, Delbridge LW, Robinson BG, Schembri G, Clifton-Bligh RJ. Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas. Clin Endocrinol (Oxf). 2018 Aug;89(2):139-147. doi: 10.1111/cen.13737. Epub 2018 May 24. PMID: 29741215.
Copy Download .nbib Format: NLM
Share it on

Clin Endocrinol (Oxf). 2018 Aug;89(2):139-147. doi: 10.1111/cen.13737. Epub 2018 May 24.

Role of DOTATATE-PET/CT in preoperative assessment of phaeochromocytoma and paragangliomas.

Clinical endocrinology

Matti L Gild, Nikita Naik, Jeremy Hoang, Edward Hsiao, Rachel T McGrath, Mark Sywak, Stan Sidhu, Leigh Walter Delbridge, Bruce Gregory Robinson, Geoff Schembri, Roderick John Clifton-Bligh

Affiliations

  1. Department of Endocrinology and Diabetes, Royal North Shore Hospital, St Leonards, NSW, Australia.
  2. Cancer Genetics Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.
  3. Department of Nuclear Medicine, Royal North Shore Hospital, St Leonards, NSW, Australia.
  4. Department of Endocrine Surgery, Royal North Shore Hospital, St Leonards, NSW, Australia.

PMID: 29741215 DOI: 10.1111/cen.13737

Abstract

CONTEXT: Diagnosis of paragangliomas (PGL) and phaeochromocytomas (PC) can be challenging particularly if the tumour is small. Detection of metastatic disease is important for comprehensive management of malignant PC/PGL. Somatostatin receptor imaging (SRI) agents have high sensitivity for these tumours, particularly the DOTA family of radiopharmaceuticals labelled with

OBJECTIVE: To describe the utility of SRI in primary assessment (ie before surgery) for PC/PGL and whether measures of maximum standardized uptake (SUVmax) could be used to distinguish between adrenal adenomas and PCs.

DESIGN: Retrospective analysis of patients with PC and PGL between 2012 and 2017.

PATIENTS: Somatostatin receptor imaging (SRI) was performed for suspected PC (n = 46) or PGL (n = 27) of which 36 were during primary assessment and 37 during secondary assessment (follow-up after surgery). For comparison of adrenal SUVmax, scans from 30 patients without suspected PC/PGL (20 with normal adrenals; 10 with incidental adenomas) were evaluated.

MEASUREMENTS: Baseline description, sensitivity, specificity, Youden's index.

RESULTS: Sensitivity of DOTATATE-PET was 88% for PC and 100% for PGL. False-negative scans were seen in 2/10 PCs < 28 mm and in 1/14 PCs > 28 mm which had features of cystic degeneration. SUVmax of PCs and PGLs was more than double compared to adrenal adenomas (P > .001).

CONCLUSION: Somatostatin receptor imaging (SRI) has high sensitivity in primary assessment for PC and PGL. We recommend that SRI should be performed as part of primary assessment in all suspected PGLs (due to higher risk of multifocal lesions) and in PCs suspected to be associated with hereditary syndromes or metastases.

© 2018 John Wiley & Sons Ltd.

Keywords: adrenocortical adenoma; paraganglioma; phaeochromocytoma; radiopharmaceuticals; somatostatin receptor

References

  1. Martucci VL, Pacak K. Phaeochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment. Curr Probl Cancer. 2014;38:7-41. - PubMed
  2. Pomares FJ, Cañas R, Rodriguez JM, et al. Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol (Oxf). 1998;48:195-200. - PubMed
  3. Ilias I, Yu J, Carrasquillo JA, et al. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic phaeochromocytoma. J Clin Endocrinol Metab. 2003;88:4083-4087. - PubMed
  4. Derlin T, Busch JD, Wisotzki C, et al. Intraindividual comparison of 123I-mIBG SPECT/MRI, 123I-mIBG SPECT/CT, and MRI for the detection of adrenal phaeochromocytoma in patients with elevated urine or plasma catecholamines. Clin Nucl Med. 2013;38:e1-e6. - PubMed
  5. Milardovic R, Corssmit EP, Stokkel M. Value of 123I-MIBG scintigraphy in paraganglioma. Neuroendocrinology. 2010;91:94-100. - PubMed
  6. Koopmans KP, Jager PL, Kema IP, Kerstens MN, Albers F, Dullaart RP. 111In-octreotide is superior to 123I-metaiodobenzylguanidine for scintigraphic detection of head and neck paragangliomas. J Nucl Med. 2008;49:1232-1237. - PubMed
  7. Nguyen HH, Proye CA, Carnaille B, Combemale F, Pattou FN, Huglo D. Tumour size: the only predictive factor for 131I MIBG uptake in phaeochromocytoma and paraganglioma. Aust N Z J Surg. 1999;69:350-353. - PubMed
  8. Bhatia KS, Ismail MM, Sahdev A, et al. 123I-metaiodobenzylguanidine (MIBG) scintigraphy for the detection of adrenal and extra-adrenal phaeochromocytomas: CT and MRI correlation. Clin Endocrinol (Oxf). 2008;69:181-188. - PubMed
  9. Tan TH, Hussein Z, Saad FF, Shuaib IL. Diagnostic performance of Ga-DOTATATE PET/CT, F-FDG PET/CT and 131-I-MIBG scintigraphy in mapping metastatic phaeochromocytoma and paraganglioma. Nucl Med Mol Imaging. 2015;49:143-151. - PubMed
  10. Mundschenk J, Unger N, Schulz S, et al. Somatostatin receptor subtypes in human phaeochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab. 2003;88:5150-5157. - PubMed
  11. Maurice JB, Troke R, Win Z, et al. A comparison of the performance of 68 Ga-DOTATATE PET/CT and 123I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2012;39:1266-1270. - PubMed
  12. Archier A, Varoquaux A, Garrigue P, et al. Prospective comparison of Ga-DOTATATE and F-FDOPA PET/CT in patients with various phaeochromocytomas and paragangliomas with emphasis on sporadic cases. Eur J Nucl Med Mol Imaging. 2016;43:1248-1257. - PubMed
  13. Chang CA, Pattison DA, Tothill RW, et al. (68)Ga-DOTATATE and (18)F-FDG PET/CT in paraganglioma and phaeochromocytoma: utility, patterns and heterogeneity. Cancer Imaging. 2016;16:22. - PubMed
  14. Dahia PL. Phaeochromocytoma and paraganglioma pathogenesis: learning from genetic heterogeneity. Nat Rev Cancer. 2014;14:108-119. - PubMed
  15. Lenders JW, Duh QY, Eisenhofer G, et al. Phaeochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915-1942. - PubMed
  16. Jafri M, Maher ER. The genetics of phaeochromocytoma: using clinical features to guide genetic testing. Eur J Endocrinol. 2012;166:151-158. - PubMed
  17. Fishbein L, Ben-Maimon S, Keefe S, et al. SDHB mutation carriers with malignant phaeochromocytoma respond better to CVD. Endocr Relat Cancer. 2017;24:L51-L55. - PubMed
  18. Aslani A, Snowdon GM, Bailey DL, Schembri GP, Bailey EA, Roach PJ. Gallium-68 DOTATATE production with automated PET radiopharmaceutical synthesis system: a three year experience. Asia Ocean J Nucl Med Biol. 2014;2:75-86. - PubMed
  19. Eble JN, Sauter G, Epstein JI, Sesterhenn IA (Eds). World Health Organization: Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press; 2004. - PubMed
  20. Janssen I, Chen CC, Millo CM, et al. PET/CT comparing (68)Ga-DOTATATE and other radiopharmaceuticals and in comparison with CT/MRI for the localization of sporadic metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging. 2016;43:1784-1791. - PubMed
  21. Algeciras-Schimnich A, Preissner CM, Young Jr WF, Singh RJ, Grebe SK. Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for phaeochromocytoma. J Clin Endocrinol Metab. 2008;93:91-95. - PubMed
  22. Bulow B, Ahren B, Swedish T. Research council study group of endocrine abdominal, adrenal incidentaloma-experience of a standardized diagnostic programme in the Swedish prospective study. J Intern Med. 2002;252:239-246. - PubMed
  23. Jacques AE, Sahdev A, Sandrasagara M, et al. Adrenal phaeochromocytoma: correlation of MRI appearances with histology and function. Eur Radiol. 2008;18:2885-2892. - PubMed
  24. Eisenhofer G, Lenders JW, Goldstein DS, et al. Phaeochromocytoma catecholamine phenotypes and prediction of tumour size and location by use of plasma free metanephrines. Clin Chem. 2005;51:735-744. - PubMed
  25. van Berkel A, Pacak K, Lenders JW. Should every patient diagnosed with a phaeochromocytoma have a (1)(2)(3) I-MIBG scintigraphy? Clin Endocrinol (Oxf). 2014;81:329-333. - PubMed
  26. Benn DE, Robinson BG, Clifton-Bligh RJ. 15 years of paraganglioma: clinical manifestations of paraganglioma syndromes types 1-5. Endocr Relat Cancer. 2015;22:T91-T103. - PubMed
  27. Goldstein RE, O'Neill Jr JA, Holcomb 3rd GW, et al. Clinical experience over 48 years with phaeochromocytoma. Ann Surg. 1999;229:755-764; discussion 764-6. - PubMed
  28. Janssen I, Chen CC, Taieb D, et al. 68 Ga-DOTATATE PET/CT in the localization of head and neck paragangliomas compared with other functional imaging modalities and CT/MRI. J Nucl Med. 2016;57:186-191. - PubMed
  29. Janssen I, Blanchet EM, Adams K, et al. Superiority of [68 Ga]-DOTATATE PET/CT to other functional imaging modalities in the localization of SDHB-associated metastatic phaeochromocytoma and paraganglioma. Clin Cancer Res. 2015;21:3888-3895. - PubMed
  30. Kong G, Grozinsky-Glasberg S, Hofman MS, et al. Efficacy of peptide receptor radionuclide therapy for functional metastatic paraganglioma and phaeochromocytoma. J Clin Endocrinol Metab. 2017;102:3278-3287. - PubMed
  31. Kratochwil C, Stefanova M, Mavriopoulou E, et al. SUV of [68 Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumours. Mol Imaging Biol. 2015;17:313-318. - PubMed

Publication Types

Grant support